September 12, 2024
World’s Largest Melanoma Research and Treatment Facility Selects RingCentral to Power Business Communications for Superior Patient Experiences
Sydney, Australia – September 12, 2024 – RingCentral, Inc. (NYSE: RNG), a leading global provider of trusted AI communications for businesses of all sizes, today announced that Melanoma Institute Australia (MIA), the world’s largest melanoma research and treatment facility, is replacing its legacy virtual PBX infrastructure with RingCentral RingEX™. The five-year contract will see all MIA staff nationally migrate to the RingCentral platform in the last quarter of 2024 to improve communications and collaboration across MIA’s multiple clinics, augmenting patient treatment and experiences.
As a not-for-profit organisation at the forefront of global advances in melanoma research and treatment, MIA is dedicated to preventing and curing melanoma through innovative world-class research, treatment and education programs. Most of MIA’s multi-disciplinary operations are based in the world’s largest melanoma research and treatment facility in North Sydney. MIA receives 2,000 new melanoma and complex skin cancer patients referrals and manages approximately 20,000 patient visits per annum.
“We needed a communications solution flexible enough to meet the individual requirements of each of our practices, while also allowing our staff to openly collaborate and share information across the broader team,” said Ernie White, CIO, Melanoma Institute Australia. “We’ve also seen an increasing number of remote engagements with patients, but we have been unable to take advantage of telehealth advances with our current communications platform. RingCentral provides the ideal solution to address all of these critical needs.”
MIA will roll out RingEX starting this October, with plans to implement the RingCentral softphone desktop client for a majority of users, as well as providing staff with the RingCentral app on their personal smartphones to enable mobility.
“As a not-for-profit, it's critical for us to streamline our costs. By using the RingCentral app, we won’t need to spend extra on desk phones or mobile device hardware. Instead, our people can still be reached on their personal mobile phones via their office extension - and we can keep their personal mobile numbers private,” said White.
RingCentral’s focus on trust, innovation, and partnership enables MIA to put connection at the centre of care, delivering superior patient experiences and bringing down costs with modern, secure, and reliable cloud communications. RingEX’s robust capabilities include HD voice, video, messaging, conferencing, and efax, as well as an integrated team workspace with fully featured messaging, collaboration, file sharing, and task management.
“Melanoma treatment involves surgeons, medical oncologists, dermatologists, pathologists, researchers, nurses, biobank specialists and psychologists. Collaboration is at the heart of enabling these multi-disciplinary teams to work well together to improve overall treatment outcomes and deliver a positive healthcare experience for patients. We’re honoured to help MIA achieve their mission of preventing and curing melanoma to save lives around the globe,” said John Poli, Industry Principal, Healthcare at RingCentral.
About RingCentral
RingCentral is a leading provider of trusted AI communications, contact centre, sales intelligence, video and hybrid event solutions. RingCentral empowers businesses with conversation intelligence and unlocks rich customer and employee interactions to provide insights and improved business outcomes. With decades of expertise in reliable and secure cloud communications, RingCentral has earned the trust of hundreds of thousands of customers and millions of users worldwide. Visit ringcentral.com to learn more.
©2024 RingCentral, Inc. All rights reserved. RingCentral, RingEX, and the RingCentral logo are trademarks of RingCentral, Inc.